Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.64M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
16.7K
-
Shares change
-
+16.7K
-
Total reported value, excl. options
-
$87.7K
-
Value change
-
+$87.7K
-
Number of buys
-
1
-
Price
-
$5.24
Significant Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q4 2023
1 filings reported holding LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value as of Q4 2023.
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.7K shares
of 1.64M outstanding shares and own 1.02% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (12.8M shares), Nantahala Capital Management, LLC (4.05M shares), Point72 Asset Management, L.P. (3M shares), Vestal Point Capital, LP (3M shares), CITADEL ADVISORS LLC (2.86M shares), Samsara BioCapital, LLC (2.78M shares), VR Adviser, LLC (2.58M shares), Rosalind Advisors, Inc. (1.89M shares), PURA VIDA INVESTMENTS, LLC (1.41M shares), and Ikarian Capital, LLC (1.25M shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.